SOPHiA GENETICS Supports Genetic Testing in Brazil
The company announced Bioma4me has implemented SOPHiA DDM™ to support its rare disorder testing capabilities
BOSTON and ROLLE, Switzerland, Jan. 25, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine to the Brazilian population, is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS’ technology to advance and streamline its genetic testing capabilities.
Related news for (SOPH)
- Molecules, Machines & Markets: Biotech Booms, AI Accelerates, and Pain Relief Gets Personal
- SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
- SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio
- SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference
